- Home
- FURY vs PLRX Comparison
FURY vs PLRX Comparison
Compare FURY & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FURY | PLRX |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 93.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FURY | PLRX |
|---|---|---|
| Price | $0.61 | $1.23 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 11 |
| Target Price | $1.40 | ★ $3.79 |
| AVG Volume (30 Days) | 663.8K | ★ 1.9M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $1.10 |
| 52 Week High | $0.89 | $14.30 |
Technical Indicators
Market Signals| Indicator | FURY | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.05 | 34.56 |
| Support Level | $0.58 | $1.19 |
| Resistance Level | $0.72 | $1.30 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 26.52 | 12.50 |
Price Performance
Historical ComparisonAbout FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.